Skip to main content
. Author manuscript; available in PMC: 2013 Aug 2.
Published in final edited form as: Immunol Invest. 2012;41(0):680–710. doi: 10.3109/08820139.2012.703745

Figure 8.

Figure 8

Despite constant susceptibility of intrasplenic MDSCs to sunitinib at MTD 40 mg/kg (D), intratumoral MDSC resistance to sunitinib was evident to a varied but sometimes profound degree (E). For the 3 tumor models compared, the disparate susceptibility of tumors to 10 days of sunitinib treatment (regression, stabilization or progression, A–C) was predictive of intratumoral (D) but not intrasplenic MDSC susceptibility (E).